Abstract
Purpose: We assessed morbidity, response and survival in patients with metastatic renal carcinoma treated with high dose intravenous interleukin-2 (IL-2) based immunotherapy with the primary renal tumor in place. Materials and Methods: We retrospectively analyzed the records of patients with metastatic renal carcinoma and the primary kidney tumor in situ who were- treated at the surgery branch of the National Cancer Institute. Of the patients 607 were treated with IL-2 based therapy. Patient age, sex, sites of extrarenal disease, morbidity, and response and survival rates were examined. Results: From 1986 to 1996, 51 patients with the majority of disease at extrarenal sites were treated with the primary tumor in place. Treatment involved IL-2 based regimens, reflecting the evolution of immunotherapy at the National Institutes of Health. When evaluating only extrarenal sites, response was complete in i and partial in 2 of the 51 cases (6%). No responses were noted in the primary renal tumor. Three patients with responses at extrarenal sites underwent nephrectomy. The duration of response in these 3 cases was greater than 88, 11 and 4 months, respectively. Median survival in all 51 patients was 13 months (range 1 to 86). Conclusions: Select patients may be treated with IL-2 based immunotherapy with the primary renal tumors in place with morbidity. A randomized study is needed to assess the role of cytoreductive nephrectomy for treating metastatic renal cell carcinoma.
Original language | English (US) |
---|---|
Pages (from-to) | 43-45 |
Number of pages | 3 |
Journal | Journal of Urology |
Volume | 162 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1999 |
Externally published | Yes |
Keywords
- Carcinoma, renal cell
- Interleukin-2
- Kidney
- Kidney neoplasms
- Neoplasm metastasis
ASJC Scopus subject areas
- Urology